Pharmaceuticals News and Research

RSS

China Sky One Medical reports financial results for third-quarter 2009

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced record financial results for the third quarter of 2009.

17 Nov 2009

BioCryst Pharmaceuticals announces sale of common stock shares

BioCryst Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.

17 Nov 2009

AAPHP: E-cigarettes are not wildly dangerous alternatives as they have been portrayed

In July of this year, the Food and Drug Administration released a study that condemned electronic cigarettes as an unsafe alternative for smokers, but not all physicians are convinced that the study was accurate or even completely transparent to the tax payers that fund them.

17 Nov 2009

First Edition: November 17, 2009

Based on today's headlines, all eyes continue to be focused on the Senate -- where Democratic leaders are still waiting for the revised Congressional Budget Office analysis of their health bill and plotting about when to hold the first procedural vote on the measure.

17 Nov 2009

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials.

From Parexel 17 Nov 2009

Researchers study different plant substances to "awaken" the latent HIV-1 virus

Researchers from the University of Cadiz and the University of Cordoba study different plant substances to "awaken" the latent HIV-1 virus, immune to the current therapy, and to obtain more effective treatments in the future.

17 Nov 2009

Consortium to define new modalities for treating hypertension and associated vascular complications

Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.

17 Nov 2009

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Illinois AARP members support health care reform plan

A new poll of Illinois AARP members released today finds strong support across party and ideological lines for elements of health care reform included in the Affordable Health Care for America Act, which recently passed the House of Representatives.

17 Nov 2009

Employers have serious concerns about healthcare reform, indicates PSG survey

Pharmaceutical Strategies Group (PSG), the nation's largest independent pharmacy benefit consulting firm, released today the results of a national survey of companies focused on their views of proposed healthcare reform legislation.

17 Nov 2009

Shire publishes new study results on INTUNIV Extended-Release Tablets

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone.

17 Nov 2009

FDA provides feedback on the pending NDA for EXALGO tablets

CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application (NDA) for the product candidate EXALGOTM (hydromorphone HCl extended release) tablets, seeking FDA approval for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time, with staff from the United States Food and Drug Administration (FDA).

17 Nov 2009

Phase II clinical study to evaluate Nanocort commenced

Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments.

17 Nov 2009

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.

17 Nov 2009

Meaningful legislation required to control biotech medicine cost, says PCMA

“Today’s New York Times’ article exposes the short-comings of the ‘pharma deal’ and how it gives with one hand while taking with the other. Rather than relying on ‘shell games’ to lower prescription drug costs, policymakers should return this debate to the need for more competition in the form of real biogenerics reform.

17 Nov 2009

FDA approves Par Pharmaceutical's new painkiller drug

Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER.

17 Nov 2009

National health leaders collaborate to create environmentally responsible health care system

Twelve national organizations representing all areas of the health sector, joined by the David Suzuki Foundation, have produced a joint statement spelling out a new commitment to creating an environmentally responsible health sector.

17 Nov 2009

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

16 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Pharmaceuticals News and Research

China Sky One Medical reports financial results for third-quarter 2009

BioCryst Pharmaceuticals announces sale of common stock shares

AAPHP: E-cigarettes are not wildly dangerous alternatives as they have been portrayed

First Edition: November 17, 2009

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Researchers study different plant substances to "awaken" the latent HIV-1 virus

Consortium to define new modalities for treating hypertension and associated vascular complications

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Illinois AARP members support health care reform plan

Employers have serious concerns about healthcare reform, indicates PSG survey

Shire publishes new study results on INTUNIV Extended-Release Tablets

FDA provides feedback on the pending NDA for EXALGO tablets

Phase II clinical study to evaluate Nanocort commenced

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

Meaningful legislation required to control biotech medicine cost, says PCMA

FDA approves Par Pharmaceutical's new painkiller drug

National health leaders collaborate to create environmentally responsible health care system

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Event guide: World ADC London eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring